Federal Register / Vol. 69, No. 4 / Wednesday, January 7, 2004 / Notices 931

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting.

Name of Committee: Secretary’s Advisory 

Committee on Xenotransplantation. 

Date: February 24, 2004. 

Open: February 24, 2004; 8 a.m. to 5:30 

p.m. 

Agenda: The SACX will focus on a variety 

of issues relating to the science and ethics of 

xenotransplantation. A significant portion of 

the meeting will be devoted to discussion of 

two draft reports by the SACX. These draft 

reports address the state of the science in 

xenotransplantation and informed consent 

issues in xenotransplantation. Additional 

presentations and discussion will focus on 

recent advances in xenotransplantation 

research, including a report of a clinical 

study of porcine islet xenotransplantation in 

type 1 diabetic patients. 

Place: Holiday Inn Select, 8120 Wisconsin 

Avenue, Bethesda, MD 20814. 

Pre-Registration: The SACX meeting is 

open to the public; however, seating is 

limited and pre-registration is encouraged. 

To register, please contact Capital Consulting 

Corporation (Terry Fisher) at 301–468–6004, 

extension 434. Individuals who plan to 

attend the meeting and who need special 

assistance or other reasonable 

accommodations should notify Ms. Fisher 

prior to the meeting. 

Public Comment: Individuals who wish to 

provide public comment (oral or written) 

should contact the SACX Executive Director, 

Dr. Mary Groesch, by telephone at 301–496–

0785 or e-mail at groeschm@od.nih.gov. 

Contact Person: Mary Groesch, Ph.D., 

Executive Director, Secretary’s Advisory 

Committee on Xenotransplantation, Office of 

Science Policy, Rockledge I, Room 750, 

Bethesda, MD 20892, 301–496–9838. 

Information is also available on the Office’s 

home page: http://www4.od.nih.gov/oba/

Sacx.htm, where an agenda and any 

additional information for the meeting will 

be posted when available.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds; 93.22, Clinical 

Research Loan Repayment Program for 

Individuals from Disadvantaged 

Backgrounds; 93.232, Loan Repayment 

Program for Research Generally; 93.39, 

Academic Research Enhancement Award; 

93.936, NIH Acquired Immunodeficiency 

Syndrome Research Loan Repayment 

Program, National Institutes of Health, HHS)

Dated: December 31, 2003. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–255 Filed 1–6–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Cancer 

Institute Special Emphasis Panel, Immune 

Escape in Human Cancer: Mechanisms and 

Therapeutic Implications. 

Date: January 19–21, 2004. 

Time: 7 p.m. to 11 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Courtyard By Marriott Shadyside/

Oakland, 5308 Liberty Avenue, Pittsburgh, 

PA 15224. 

Contact Person: Shakeel Ahmad, Ph.D., 

Scientific Review Administrator, Research 

Programs Review Branch, National Cancer 

Institute, Division of Extramural Activities, 

6116 Executive Blvd., Bethesda, MD 20892, 

(301) 594–0114, amads@mail.nih.gov.

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS).

Dated: December 30, 2003. 

Anna P. Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–253 Filed 1–6–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: Center for Inherited 

Disease Research Access Committee. 

Date: January 8, 2004. 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites, Washington, DC. 

Contact Person: Rudy O. Pozzatti, PhD., 

Scientific Review Administrator. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS)

Dated: December 31, 2003. 

Anna P. Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–254 Filed 1–6–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. appendix 2), notice 

is hereby given of a meeting of the 

National Advisory Council on Drug 

Abuse. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should

932 Federal Register / Vol. 69, No. 4 / Wednesday, January 7, 2004 / Notices 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Advisory 

Council on Drug Abuse. 

Date: February 11–12, 2004. 

Closed: February 11, 2004, 2 p.m. to 3:30 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. 

Open: February 12, 2004, 9 a.m. to 3:30 

p.m. 

Agenda: This portion of the meeting will 

be open to the public for announcements and 

reports of administrative, legislative and 

program developments in the drug abuse 

field. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse Research 

Programs, National Institutes of Health, HHS)

Dated: December 31, 2003. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–251 Filed 1–6–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, 

‘‘Technical Support for Constituency 

Outreach and Research Dissemination’’. 

Date: January 22, 2004. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6101 

Executive Boulevard, Room 220, Rockville, 

MD 20852, (Telephone Conference Call). 

Contact Person: Lyle Furr, Contract Review 

Specialist, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 220, MSC 8401, 6101 Executive 

Boulevard, Bethesda, MD 20892–8401, (301) 

435–1439.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse Research 

Programs, National Institutes of Health, HHS)

Dated: December 31, 2003. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–252 Filed 1–6–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) will publish a summary of 

information collection requests under 

OMB review, in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

documents, call the SAMHSA Reports 

Clearance Officer on (301) 443–7978. 

Substance Abuse Prevention and 

Treatment Block Grant Regulations—45 

CFR Part 96 (OMB No. 0930–0163; 

Extension, no change) 

These regulations provide guidance to 

States regarding the Substance Abuse 

Prevention and Treatment Block Grant 

legislation, including the information 

collection requirements regarding the 

sale or distribution of tobacco products 

to individuals under age eighteen. The 

rule implements the reporting and 

recordkeeping requirements of 42 U.S.C. 

300x21–35 and 51–64 by specifying the 

content of the States’ annual reports on 

and application for block grant funds. 

The reporting burden hours are counted 

towards the total burden for the 

Substance Abuse Prevention and 

Treatment Block Grant Application 

Format (OMB No. 0930–0080) and the 

Substance Abuse Prevention and 

Treatment Block Grant Synar Report 

Format (OMB No. 0930–0222) for which 

separate approval is obtained. The total 

annual reporting and recordkeeping 

burden estimate is shown below:

45 CFR citation Number of respondents 6

Responses/respondent Hours/response Total hour burden 

Reporting Burden

Annual Report: 

96.122(d) 1 ................................................................................................ 60 1 0 0 

96.122(f)(1)–(5)(iv); 96.126(f) ................................................................... 60 1 152 9,120 

96.122(f)(5)(v) 2 ......................................................................................... 59 1 2 118 

96.122(f)(6) 3 ............................................................................................. 0 0 0 0 

96.130(e)(1–3) .......................................................................................... 59 1 15 885 

96.134(d) .................................................................................................. 60 1 16 960 

State Plan: 

96.122(g) .................................................................................................. 60 1 162 9,720